Wuhan Institute of Biological Products Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Subsidiary
- Established
- 1990-03-08
- Employees
- -
- Market Cap
- -
- Website
- http://www.wibp.com.cn
Clinical Trials
3
Active:0
Completed:0
Trial Phases
3 Phases
Phase 1:1
Phase 2:1
Phase 4:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (33.3%)Phase 2
1 (33.3%)Phase 4
1 (33.3%)Clinical Study of F61 Injection in Healthy Chinese Subjects
Phase 1
- Conditions
- COVID-19
- Interventions
- Drug: F61 injectionDrug: F61 Placebo
- First Posted Date
- 2022-08-02
- Last Posted Date
- 2022-08-02
- Lead Sponsor
- Wuhan Institute of Biological Products Co., Ltd
- Target Recruit Count
- 40
- Registration Number
- NCT05483504
To Identify the Immunogenicity and Safety of QIV in Children Aged 3-8 Years
Phase 4
- Conditions
- Influenza
- First Posted Date
- 2022-05-25
- Last Posted Date
- 2022-05-25
- Lead Sponsor
- Wuhan Institute of Biological Products Co., Ltd
- Target Recruit Count
- 360
- Registration Number
- NCT05389137
- Locations
- 🇨🇳
Yangchun Center for Disease Control and Prevention, Guangzhou, Guangdong, China
A Study to Evaluate the Efficacy and Safety of DXP604 in Patients With Mild to Moderate COVID-19
Phase 2
- Conditions
- COVID-19
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2022-05-19
- Lead Sponsor
- Wuhan Institute of Biological Products Co., Ltd
- Target Recruit Count
- 50
- Registration Number
- NCT05381519
News
No news found